225. 先天性腎性尿崩症 Congenital nephrogenic diabetes insipidus Clinical trials / Disease details

臨床試験数 : 15 / 薬物数 : 48 - (DrugBank : 18) / 標的遺伝子数 : 31 - 標的パスウェイ数 : 65

diseases per page:

Showing 1 to 10 of 15 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05044611 (ClinicalTrials.gov)	April 1, 2022	27/8/2021	AMIloride for the Treatment of Nephrogenic Diabetes Insipidusfor Patients With Bipolar Disorder Trea ...	AMIloride for the Treatment of Nephrogenic Diabetes Insipidusfor Patients With Bipolar Disorder Trea ...	Bipolar Disorder	Drug: Anhydrous Amiloride Hydrochloride;Drug: Placebo	Assistance Publique - Hôpitaux de Paris	NULL	Not yet recruiting	18 Years	N/A	All	148	Phase 4	NULL
2	NCT05190744 (ClinicalTrials.gov)	March 1, 2022	29/12/2021	PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKD Treated With Tolvaptan, and Severely Po ...	A Multi-center, Open-Label, Exploratory Study to Assess the Efficacy of PB in Decreasing the Urine O ...	Autosomal Dominant Polycystic Kidney Disease;Nephrogenic Diabetes Insipidus;Acquired Nephrogenic Dia ...	Drug: PB	Mayo Clinic	Hopital du Sacre-Coeur de Montreal	Recruiting	18 Years	N/A	All	20	Phase 2	United States
3	NCT04939753 (ClinicalTrials.gov)	May 26, 2021	27/4/2021	Nephrogenic Diabetes InsipidusDuring Prolonged Sevoflurane Sedation in the ICU: a Retrospective Anal ...	Incidence of Nephrogenic Diabetes InsipidusDuring Prolonged Sevoflurane Sedation in the Intensive Ca ...	Nephrogenic Diabetes Insipidus	Drug: Sevoflurane	Universitair Ziekenhuis Brussel	NULL	Recruiting	18 Years	N/A	All	1000		Belgium
4	EUCTR2020-002204-38-DK (EUCTR)	24/11/2020	07/05/2020	Treatment of the genetic disease nephrogenic diabetes insipidus with the antifungal drug Fluconazole	Treatment of congenital nephrogenic diabetes insipidus with fluconazole, an antifungal medication	Nephrogenic diabetes insipidus MedDRA version: 21.0;Level: LLT;Classification code 10012600;Term: Di ...	INN or Proposed INN: Fluconazole Other descriptive name: FLUCONAZOLE	Claus Bistrup	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	10	Phase 2	Denmark
5	JPRN-jRCTs031180369	12/04/2018	18/03/2019	Tolvaptan for nephrogenic diabetes insipidus	Exploratory study of tolvaptan use for nephrogenic diabetes insipiduscaused by mutation in vasopress ...	Nephrogenic diabetes insipidus Nephrogenic diabetes insipidus, polyuria;D018500	Starting tolvaptan from 60 mg and dose up to 90mg and 120mg in every 1 or 2 days.	Makita Noriko	NULL	Recruiting	>= 20age old	Not applicable	Both	3	Phase 1-2	Japan
6	EUCTR2016-001591-30-DK (EUCTR)	06/11/2017	09/03/2017	Treatment of congenital nephrogenic diabetes insipidus with riociguat or sildenafil	Treatment of congenital nephrogenic diabetes insipiduswith a guanylate cyclase stimulator, riociguat ...	Nephrogenic diabetes insipidusbecause of AVP2R-mutation MedDRA version: 20.0;Level: LLT;Classificati ...	Trade Name: Adempas Product Name: Adempas INN or Proposed INN: RIOCIGUAT Other descriptive name: RIOCIG ...	Odense University Hospital	NULL	Not Recruiting			Female: no Male: yes	2	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	Denmark
7	NCT02967653 (ClinicalTrials.gov)	July 13, 2017	15/11/2016	Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus	Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus: A Randomized Contr ...	Lithium Use, Nephrogenic Diabetes Insipidus	Drug: Atorvastatin	Lady Davis Institute	NULL	Completed	18 Years	85 Years	All	60	Phase 2	Canada
8	JPRN-UMIN000021708	2016/04/18	18/04/2016	A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipiduscaused by mutati ...	A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipiduscaused by mutati ...	Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene	Administration of Tolvaptan once per day (60mg/day, 90mg/day, 120mg/day), each dose for two days.	Department of Nephrology and Endocrinology, The University of Tokyo Hospital	NULL	Recruiting	20years-old	Not applicable	Male and Female	3	Not selected	Japan
9	NCT02460354 (ClinicalTrials.gov)	September 2015	29/5/2015	Metformin and Congenital Nephrogenic Diabetes Insipidus	Use of Metformin to Treat Patients With Congenital Nephrogenic Diabetes Insipidus (NDI)	Diabetes Insipidus	Drug: Metformin	Emory University	NULL	Terminated	18 Years	N/A	Male	2	Phase 1	United States
10	EUCTR2012-001809-24-NL (EUCTR)	31/07/2013	06/09/2012	A diminished concentrating ability of the kidneys due to lithium prescription: how many and whom is ...	Evaluation of urinary concentrating defects in lithium treated patients with a dDAVP test - Nephroge ...	lithium-induced urinary concentrating defects (nephrogenic diabetes insipidus) MedDRA version: 15.0; ...	Trade Name: Desmopressine nasal spray 10 mg/ml, flacon 60 doses Product Name: Desmopressine nasal spray ...	Radboud University Nijmegen Medical Centre	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Netherlands

First Previous1 2Next Last